Repare Therapeutics Inc. Logo

Repare Therapeutics Inc.

Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.

RPTX | US

Overview

Corporate Details

ISIN(s):
US7602731025
LEI:
Country:
United States of America
Address:
7171 FREDERICK BANTING, SAINT-LAURENT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Repare Therapeutics Inc. is a clinical-stage precision oncology company that discovers and develops novel cancer therapies. The company's core strategy is based on synthetic lethality, a concept where combinations of genetic mutations lead to cell death. Repare utilizes its proprietary, genome-wide, CRISPR-enabled SNIPRx® platform to systematically identify and validate new therapeutic targets. Its pipeline focuses on developing highly targeted, small molecule drugs designed to treat cancers with specific genomic instabilities, particularly those related to DNA damage repair, addressing patient populations with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Repare Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Repare Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Repare Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea
456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden
GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium
GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland
GALD
GALECTIN THERAPEUTICS INC Logo
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
United States of America
GALT
Galecto, Inc. Logo
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
United States of America
GLTO
Galmed Pharmaceuticals Ltd. Logo
Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.
United States of America
GLMD
GC CELL CORPORATION Logo
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea
144510
Gelteq Ltd Logo
Ingestible gel platform for enhanced oral delivery of drugs & nutrients for human & animal health.
United States of America
GELS

Talk to a Data Expert

Have a question? We'll get back to you promptly.